The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 28th Oct 2014 09:18

Afren: Credit Suisse lowers target price from 132p to 115p staying with its outperform rating.African Barrick Gold: Westhouse moves target price from 230p to 240p and keeps an add rating.Anglo American: Investec reduces target price from 1603p to 1588p and keeps a buy recommendation.APR Energy: Liberum Capital upgrades to hold with a target price of 385p. Jefferies reduces target price from 1250p to 670p, while its buy recommendation remains unchanged. JP Morgan reduces target price from 1008p to 801p and leaves its overweight rating unchanged.Aviva: Societe Generale raises target price from 580p to 650p maintaining a buy recommendation.Cairn Energy: Credit Suisse cuts target price from 288p to 266p and retains an outperform rating.Croda International: Goldman Sachs reduces target price from 2750p to 2675p, while leaving its buy recommendation unaltered.Direct Line: UBS cuts target price from 304p to 282p and stays with its buy recommendation.Dunelm: Canaccord initiates with a target price of 925p and a buy recommendation.easyJet: Deutsche Bank reduces target price from 1935p to 1830p keeping a buy recommendation.Elementis: Goldman Sachs cuts target price from 345p to 330p and stays with its neutral rating.EnQuest: Credit Suisse cuts target price from 150p to 122p reiterating an outperform rating.Essentra: Goldman Sachs reduces target price from 970p to 880p and retains a buy recommendation.Faroe Petroleum: Credit Suisse lowers target price from 138p to 133p and reiterates a neutral rating.GKN: Westhouse cuts target price from 450p to 400p and leaves its buy recommendation unchanged.GlaxoSmithKline: Jefferies cuts target price from 1400p to 1350p and reiterates a hold recommendation.HSBC Holdings: Deutsche Bank lowers target price from 640p to 638p and retains its hold recommendation.ICAP: Morgan Stanley ups target price from 386p to 408p staying with its equal-weight rating.LSE: Morgan Stanley raises target price from 2098p to 2210p and keeps an overweight rating.Mothercare: JP Morgan cuts target price from 267p to 238p maintaining an overweight rating.Old Mutual: Barclays downgrades to equal-weight with a target price of 205p. JP Morgan shifts target price from 223p to 225p and reiterates an overweight rating.Petra Diamonds: Panmure Gordon cuts target price from 171p to 155p leaving its sell recommendation unchanged.Premier Foods: Societe Generale cuts target price from 70p to 35p and retains its hold recommendation.Premier Oil: Credit Suisse reduces target price from 392p to 355p and reiterates an outperform rating.Shire: Cenkos increases target price from 5200p to 5347p keeping its buy recommendation.SIG: Numis cuts target price from 230p to 200p maintaining its buy recommendation.Standard Chartered: Numis reduces target price from 1400p to 1200p downgrading from add to hold. Investec reduces target price from 1450p to 1350p and stays with its buy recommendation.Stratex: Northland lowers target price from 9.3p to 7.7p and stays with its buy recommendation.Synthomer: Goldman Sachs lowers target price from 260p to 250p and reiterates its neutral rating. Canaccord cuts target price from 283p to 258p and retains a buy recommendation.Tullett Prebon: Morgan Stanley ups target price from 254p to 270p and retains its equal-weight rating.Tullow Oil: Credit Suisse lowers target price from 800p to 790p and keeps a neutral rating.UBM: Canaccord ups target price from 600p to 620p upgrading from hold to buy.Vedanta Resources: Deutsche Bank reduces target price from 1215p to 1180p maintaining a buy recommendation.Victrex: Goldman Sachs reduces target price from 2110p to 2010p and keeps a buy recommendation.Wetherspoon (JD): Numis ups target price from 900p to 950p leaving its add rating unchanged.
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.